66623-79-8|5-Bromo-2-methoxythioanisole| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 66623-79-8 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 66623-79-8 ]

CAS No. :	66623-79-8
Formula :	C₈H₉BrOS
M.W :	233.13
SMILES Code :	COC1=C(SC)C=C(Br)C=C1
MDL No. :	MFCD22488925
InChI Key :	ADJYZINEAMDEFL-UHFFFAOYSA-N
Pubchem ID :	11831323

Safety of [ 66623-79-8 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

Computational Chemistry of [ 66623-79-8 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	6
Fraction Csp3	0.25
Num. rotatable bonds	2
Num. H-bond acceptors	1.0
Num. H-bond donors	0.0
Molar Refractivity	52.36
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	34.53 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.54
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	3.1
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.18
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	3.15
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.05
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	3.0

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.51
Solubility	0.072 mg/ml ; 0.000309 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.49
Solubility	0.0749 mg/ml ; 0.000321 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.88
Solubility	0.0306 mg/ml ; 0.000131 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	Yes
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.52 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.07

Application In Synthesis of [ 66623-79-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 66623-79-8 ]

[ 66623-79-8 ] Synthesis Path-Downstream 1~21

1
[ 104-92-7 ]
[ 20828-73-3 ]
[ 66623-79-8 ]

References: [1]Tetrahedron Letters,1998,vol. 39,p. 4657 - 4658.

3
[ 2388-73-0 ]
[ 66623-79-8 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydrogen sulfate; bromine; In dichloromethane;	EXAMPLE 206B 4-Bromo-2-methylthioanisole To a 0 C. solution of 2-methylthioanisole (0.50 g, 3.57 mmol) in methylene chloride (40 mL) was added powdered Fe (20 mg, 0.36 mmol) followed by dropwise addition of bromine (0.58 g, 3.54 mmol). After 30 minutes, the starting material had been consumed (thin layer chromatography, hexanes). The excess bromine was quenched by adding a solution of NaHSO3 and stirring for several minutes. The methylene chloride layer was separated, and the aqueous phase extracted with additional methylene chloride. The combined methylene chloride solution was dried over MgSO4, filtered, and concentrated in vacuo. The resultant oil was chromatographed (flash silica gel, ethyl acetate/hexanes 1:49) to provide the product (yield: 0.74 g, 96%). 1H NMR (300 MHz, CDCl3) δ 2.30 (s, 3H), 2.45 (s, 3H), 7.00 (d, J=8.4 Hz, 1H), 7.27-7.33 (m, 2H).

References: [1]Patent: US6307047,2001,B1 .

4
[ 66623-79-8 ]
C₁₈H₁₈O₂S [ No CAS ]

References: [1]Patent: EP2829537,2015,A1 .

5
[ 66623-79-8 ]
C₂₀H₂₀O₃S [ No CAS ]

References: [1]Patent: EP2829537,2015,A1 .

6
[ 66623-79-8 ]
C₂₀H₁₈O₂S [ No CAS ]

References: [1]Patent: EP2829537,2015,A1 .

7
[ 66623-79-8 ]
C₃₇H₃₂O₄S [ No CAS ]

References: [1]Patent: EP2829537,2015,A1 .

8
[ 66623-79-8 ]
[ 529-34-0 ]
C₁₈H₁₈OS [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
75%		13.6 g (561 mmol) of magnesium was added to 1,120 ml of tetrahydrofuran and heated at 50C, and 130.8 g (561 mmol) of the benzene compound of the above formula (14) was added dropwise to the resulting solution over 2 hours. Thereafter, a reaction was carried out at 65C for 1 hour to prepare a Grignard solution. [0100] 1,120 ml of toluene was added to this solution, and 73.8 g (505 mmol) of 1-tetralone was added dropwise to the resulting solution so as to carry out a reaction at 50C for 3 hours. After the end of the reaction, 299 g of 10 % hydrochloric acid was added to carry out a reaction at 30C for 3 hours, the reaction solution was washed in water, the solvent was removed, and 477 ml of methanol was added for recrystallization to obtain a compound represented by the following formula (15) as 107.6 g (379 mmol, yield of 75%) of a white solid.

References: [1]Patent: EP2829537,2015,A1 .Location in patent: Paragraph 0099; 0100.

9
[ 2388-73-0 ]
[ 66623-79-8 ]
(4-bromo-2-methoxyphenyl)(methyl)sulfane [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With bromine; iron; In dichloromethane; at 20℃;	To a solution of 2-methylthioanisole (2 g, 13 mmol) in CH2CI2 (50 mL) was added powdered Fe (0.73 g, 1.3 mmol), followed by a dropwise addition of bromine (2.1 g, 13 mmol). After stirred at room temperature for 30 minutes, the starting material had been consumed. The excess bromine was quenched by adding a saturated aqueous solution of NaHS03 and the mixture was stirred for several minutes. The CH2CI2 layer was separated, and the aqueous phase extracted with CH2CI2. The combined CH2CI2 extracts were dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatograph using Petroleum Ether to afford a mixture of (5-bromo-2-methoxyphenyl)(methyl)sulfane and (4-bromo- 2-methoxyphenyl)(methyl)sulfane as a yellow oil. (1 .2 g, 40%). MS (ESI) m/z: 234 [M+H]+.

References: [1]Patent: WO2015/100609,2015,A1 .Location in patent: Page/Page column 41.

10
[ 624-92-0 ]
[ 21702-84-1 ]
[ 66623-79-8 ]